Basir Gill

Finerenone extends cardiorenal event-free survival in CKD + T2D patients (FIDELITY pooled analysis, n=12,990): ⏱️ Mean event-free survival from age 65: ▪️ Finerenone: 11.5 years ▪️ Placebo: 10.2 years ▪️ Gain: +1.3 years (95% CI 0.6–2.0; P<0.001) 📉 HR for composite cardiorenal outcome: 0.84 (95% CI 0.78–0.90) ✅ Benefit consistent across eGFR & albuminuria subgroups 📊 Gains observed from age 55 (+1.2 yrs) to 75 (+0.8 yrs) Beyond hazard ratios — lifetime absolute benefit estimates to support real-world clinical decisions 🎯 #Cardiology #Nephrology #Finerenone #CKD #T2D #EHJ @mvaduganathan @safchat @ShahzebKhanMD @brendonneuen @DrMarthaGulati @hvanspall @ShelleyZieroth @goKDIGO @ehj_ed @EJHFEiC academic.oup.com/eurheartj/adva…

@CMichaelGibson Happy Easter Dr. Gibson! A Bundle of Blessings for you and yours!

Just keeping it real from the Gibson house #cmgsees Happy #easter

Managing bleeds on anticoagulant therapy: a practical guide for clinicians. doi.org/10.1093/ehjacc… Contributions from Baim President and CEO, @CMichaelGibson and Baim faculty, Dr. Dominick Angiolillo, and Prof. Gilles Montalescot. #BaimInstitute #ClinicalResearch

We should have been stopping aspirin.

Download the lipid guidelines slides here clinicaltrialresults.org/wp-content/upl…

WikiDoc.org now handles about a billion page requests per year ! 20 years >110,000 chapters created by thousands of MDs Millions of edits Free Collaborative authoring International faculty Updated continuously based on content from leading journals

With 60 CEC programs, 30-40 IDMCs, 30-40 core lab programs, numerous full service trials, and hundreds of thousands of patients in upcoming trials, @BaimInstitute is growing exponentially !!! We need world class project managers ! Send your CV to Gail.Sullivan@BaimInstitute.org BaimInstitute.org

When humans conversationally present medical scenarios to #AI chatbots, the accuracy of diagnoses is < 35% sciencenews.org/article/medica… Original article in Nature Medicine nature.com/articles/s4159…

All for IMRAN KHAN this is the beauty of cricket. #T20WorldCup

I heard from an administrative colleague about a meeting that made his jaw drop. He was summoned to an “emergency summit” to discuss his health system’s decline in heart failure admissions. The cardiology department had been focused on reducing heart failure admissions and readmissions The focus of the “summit” would make anyone with a consicence blush: How do we increase our heart failure admissions? The most benign view is that the system wanted to get a larger share of a shrinking pie of admissions in the community. But the subtext of the meeting was unmistakeable: when patients win, hospitals lose. In many ways, outpatient management of heart failure was “too effective.” High margin heart failure admissions and ICU stays were shrinking in number. And, yet, rather than declaring victory and the stunning success of the cardiology team, the hospital was in a panic. Revenue was declining—and the hospital’s finances were suddenly in disarray. They needed more admissions—and fast. Said another way, they needed more sick people to need their services. Traditional administrators would say the dynamic is an outgrowth of our broken fee-for-service health systems. That incentives from value-based care do not make up for loss of volume. But there’s something more nefarious in this short vignette: it’s the unquestioned institutional focus on finance over health. “No margin, no mission,” some might glibly say. But has the mission been fundamentally corrupted? 
Is our mission: Keeping our beds full? Our margins high? Our doors open? 
Our teams employed at all costs? Or is our mission to promote the health and well-being of the community? We have clearly lost our way in important respects. For if it was the latter, the emergency heart failure admissions meeting would not be an institutional crisis, but a celebration. Celebration of community health. 
Celebration that patients were able to spend more time at home than in the hospital. Celebration that patients were healthier and so needed services less, not more. But, yet, health service organizations too often measure themselves by traditional business metrics: Volume. Revenue.
 Profit. Which of course are the wrong metrics for (mostly not-for-profit) health systems and hospitals who are chartered to serve the public good. It is the (hard) work of hospital administration to work proactively with payers to ensure that they are financially rewarded for doing the right thing. Not to blame the system and perverse incentives. forbes.com/sites/sachinja…

Surgical and Procedural Bleed Risk Stratification for Anticoagulated Patients Undergoing Planned Surgery. doi.org/10.1016/j.jtha… Contributions from Baim faculty, Dr. Jean Connors. #BaimInstitite #ClinicalResearch

Join us for an important online session by CVHRI on “Collaboration Without Compromise: Ethics in Research Teams”, led by our star fellow Dr. Saad ur Rahman, MD (Cardiology Fellow, Lahey Hospital & Medical Center; Vice Chair Research & Innovation, CVHRI) ♥️🔥🫀

Cardiovascular Adverse Effects of Common Non-Oncologic Medications: From Mechanisms to Clinical Management. doi.org/10.1093/ehjcvp… Contributions from Baim CEO, @CMichaelGibson and Baim faculty, @ceciliabahit. #BaimInstitute #ClinicalResearch #Cardiology

Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%. The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year. There was no increase in mild or severe bleeding or intracranial bleeding 63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin All benefit with no increase in bleeding risk View slides here: clinicaltrialresults.org/dr-mike-sharma…

We report that the insertion of a column of beads called DrugSorb designed to absorb ticagrelor from the bloodstream during bypass surgery can reduce severe #CABG bleeding in a pre-specified analysis. jtcvs.org/article/S0022-…

The recording from today's Baim Grand Rounds with Dr. Steven Nissen on "Obesity and Cardiovascular Disease" is now available on the Baim website. You can find it here: baiminstitute.org/index.php/obes…

FDA embraces Bayesian statistical methods to improve efficiency of clinical trials fda.gov/news-events/pr…

@CMichaelGibson Get the backstory! podcasts.apple.com/us/podcast/fro…

Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types. ja.ma/4aKdivK

Reminder! Please join us on Monday, January 5, 2026, from 9:30-10:30 am EST for Baim Grand Rounds, featuring Dr. Gilles Montalescot, who will present “Antiplatelet Therapy in PCI for Acute MI.” Zoom link: us06web.zoom.us/j/85896996821